DFTX
Definium Therapeutics, Inc.NASDAQHEALTHCAREBIOTECHNOLOGY
Key Statistics
Market Cap
$2.14B
P/E Ratio
—
EPS
$-2.06
Beta
2.56
52W High
$21.74
52W Low
$5.36
50-Day MA
$17.77
200-Day MA
$12.70
Dividend Yield
—
Profit Margin
0.00%
Forward P/E
—
PEG Ratio
—
About Definium Therapeutics, Inc.
Definium Therapeutics, Inc., a clinical stage biopharmaceutical company, develops novel products to treat brain health disorders. The company is headquartered in New York, New York.
Fundamentals
| Revenue (TTM) | 0 |
| Gross Profit (TTM) | 0 |
| EBITDA | $-166.28M |
| Operating Margin | 0.00% |
| Return on Equity | -64.10% |
| Return on Assets | -28.00% |
| Revenue/Share (TTM) | $0.00 |
| Book Value | $3.36 |
| Price-to-Book | 6.21 |
| Price-to-Sales (TTM) | — |
| EV/Revenue | - |
| EV/EBITDA | — |
| Quarterly Earnings Growth (YoY) | 0.00% |
| Quarterly Revenue Growth (YoY) | 0.00% |
| Shares Outstanding | $99.70M |
| Float | $93.74M |
| % Insiders | 1.39% |
| % Institutions | 71.79% |
Historical Volatility
HV 10-Day
69.07%
HV 20-Day
58.77%
HV 30-Day
51.12%
HV 60-Day
58.82%
HV Rank
6.7%
Volatility is currently expanding
Analyst Ratings
Consensus ($35.23 target)
3
Strong Buy12
BuyData last updated: 4/10/2026